<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962868</url>
  </required_header>
  <id_info>
    <org_study_id>87RI18_0002 (RESECT COLON)</org_study_id>
    <nct_id>NCT03962868</nct_id>
  </id_info>
  <brief_title>Endoscopic Submucosal Dissection (ESD) Versus Endoscopic Mucosal Resection (EMR) for Large Non Pedunculated Colonic Adenomas: a Randomized Comparative Trial</brief_title>
  <acronym>RESECT COLON</acronym>
  <official_title>Endoscopic Submucosal Dissection (ESD) Versus Endoscopic Mucosal Resection (EMR) for Large Non Pedunculated Colonic Adenomas: a Randomized Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initially developed in Japan for the treatment of endemic superficial gastric cancers,
      endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic
      lesions of the digestive tract into a single fragment. It allows a perfect pathological
      analysis, and decreases the rate of recurrence of the adenoma to less than 2% However, this
      procedure, which is technically more challenging, is also more risky (perforation rate at 4%
      vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of
      equipment, but this difference can be offset by the cost of the high number of iterative
      colonoscopies required in patients who have had endoscopic resection by WF-EMR.

      Scientific debate is agitating the Western world1,2 and Japanese experts do not perform
      WF-EMR anymore, whereas no comparative prospective study has compared these two procedures.

      We therefore propose to compare these two endoscopic resection strategies in terms of
      recurrence rate at 6 months and to estimate the differential cost-effectiveness and
      cost-utility ratios over a 36-month time horizon.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">October 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare recurrence rate at follow-up colonoscopy</measure>
    <time_frame>Month 6</time_frame>
    <description>Compare between two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of R0 resection rate</measure>
    <time_frame>Month 1</time_frame>
    <description>Compare between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative complications rate after treatment</measure>
    <time_frame>Month 1</time_frame>
    <description>Compare between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic curative resection rate without surgery</measure>
    <time_frame>Month 36</time_frame>
    <description>Compare between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life over time</measure>
    <time_frame>Month 36</time_frame>
    <description>Compare between two groups at Month 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness ratio</measure>
    <time_frame>Month 36</time_frame>
    <description>Compare between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility ratio</measure>
    <time_frame>Month 36</time_frame>
    <description>Compare between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative surgical referral rate</measure>
    <time_frame>Month 36</time_frame>
    <description>Compare between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the proportion of technical failure</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Colonic Polyp</condition>
  <arm_group>
    <arm_group_label>Endoscopic submucosal dissection (ESD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic Mucosal Resection (WF-piece meal EMR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Experimental procedure : ESD</intervention_name>
    <description>ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (&lt;1.5%)</description>
    <arm_group_label>Endoscopic submucosal dissection (ESD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Comparison procedure: WF-piece meal EMR</intervention_name>
    <description>WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).</description>
    <arm_group_label>Endoscopic Mucosal Resection (WF-piece meal EMR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient suffering from non-pedunculated polyp suspected larger than 25 mm in the colon

          -  Colon localization beyond 15 cm of the anal margin.

          -  Indication for endoscopic treatment

          -  Patients aged ≥ 18 years old

          -  Patients able to fill in questionnaires written in French

        Exclusion Criteria:

          -  Prior endoscopic resection attempt

          -  Contra-indication to colonoscopy

          -  Contra-indication to general anesthesia

          -  Inability to stop antiplatelet agents and anti-coagulant according to the European
             Society of Gastro-Intestinal Endoscopy guidelines.

          -  Recurrent adenoma: post-endoscopic or surgical resection

          -  Pregnant or lactating women

          -  Genetic polyposis (Familial Adenomatous Polyposis, Lynch Syndrome, Peutz-Jeghers
             Syndrome)

          -  Inability to provide informed consent

          -  Patient under legal protection and or deprived of liberty by judicial or
             administrative decision

          -  Patient already participating in an interventional clinical research protocol

          -  Patient who cannot be followed for the duration of the study

          -  Non-pedunculated polyp ≤ 25 mm

          -  Suspicion of deep submucosal cancer by analysis of vascular pattern and pit pattern
             (SANO IIIB, KUDO Vn)

          -  Non granular pseudodepressed Laterally spreading tumors due to the high risk of
             non-visible submucosal cancer

          -  Polyp involving the appendice deeply (type 2 or 3 of classification of Toyonaga)

          -  Polyp inside the ileo-caecal valvula

          -  Tattoing under the lesion

          -  Inflammatory Bowel Disease with expected fibrosis (Crohn disease or ulcerative
             colitis)

          -  Colon localization &lt; 15 cm of the anal margin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JEREMIE JACQUES, Dr</last_name>
    <phone>+ 33 (0) 5 55 05 88 72</phone>
    <email>jeremie.jacques@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinics Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert Piessevaux</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremie JACQUES</last_name>
      <phone>+ 33 (0) 5 55 05 88 72</phone>
      <email>jeremie.jacques@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jean Mermoz Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Lepilliez</last_name>
      <email>lepilliezvincent@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Pioche</last_name>
      <email>mathieu.pioche@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Chevaux</last_name>
      <email>jb.chevaux@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislas Chaussade</last_name>
      <email>stanislas.chaussade@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontchaillou Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothée Wallenhorst</last_name>
      <email>timothee.wallenhorst@chu-rennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colonic Polyp</keyword>
  <keyword>large non pedunculated</keyword>
  <keyword>colonic adenoma</keyword>
  <keyword>Endoscopic submucosal dissection</keyword>
  <keyword>Endoscopic Mucosal Resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

